Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 10/20 | 0.48 |
| ▸ | RARB | P10826 | 9/20 | 0.48 |
| ▸ | RARG | P13631 | 9/20 | 0.48 |
| ▸ | RXRA | P19793 | 3/20 | 0.48 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705630 | 0.87 | RARA (0.48) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8557715 | 0.87 | RARA (0.48) | RARARARBRARGRXRANR2E1 | |
| Methane SCHEMBL8560238 | 0.82 | RARA (0.47) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6293940 | 0.81 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6293941 | 0.81 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8633015 | 0.81 | RARA (0.48) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8560773 | 0.81 | RARA (0.48) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8560240 | 0.81 | RARA (0.46) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6759497 | 0.79 | RARA (0.51) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6759496 | 0.79 | RARA (0.51) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| US-5808124-A | BINDING TO RETINOID RECEPTORS | ALLERGAN (US) | 1998-09-15 | — | — | US | disclosed |
| US-5773594-A | TREATING SKIN DISORDERS, REDUCING SIDE EFFECTS OF OTHER RETINOIDS | ALLERGAN (US) | 1998-06-30 | — | — | US | disclosed |
| US-5763635-A | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-06-09 | — | — | US | disclosed |
| US-5747542-A | SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN (US) | 1998-05-05 | — | — | US | disclosed |
| US-5741896-A | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-04-21 | — | — | US | disclosed |
| US-5723666-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.